Phaseline

Companies › Auricula Biosciences

Auricula Biosciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
WEF-001
MMAE antibody-drug conjugate
–Phase 1Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaJan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07148128WEF-001Phase 1Advanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaOncologyJan 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.